₹ 272000 / 3200 Shares Shares
Minimum Investment
₹80-85 per equity share
01 Dec 2025
03 Dec 2025
1600
₹ 272000
₹80-85
08 Dec 2025
33,08,800 shares(aggregating up to ₹28.12 crore)
₹10 Per Equity Share
3200 Shares
3200 Shares
Incorporated in January 2021, Invicta Diagnostic Limited offers radiology and pathology solutions. It provides pathology and radiology testing comprising imaging, radiology, pathology, and teleradiology services under the brand 'PC Diagnostics” through 7 diagnostic centres and a central laboratory across Mumbai in Maharashtra. Invicta Diagnostics Limited, trading as PC Diagnostics, is a Mumbai-based diagnostic services company specializing in integrated pathology and radiology solutions. The company follows a hub‑and‑spoke model across the Mumbai Metropolitan Region, featuring: A flagship hub offering full-spectrum pathology and advanced radiology (CT, MRI) at Thane West Three other centres - Bhayandar, Byculla, Marol - offering specialized diagnostic services Basic imaging, including X-ray and ultrasound, and sample collection were the focus of spokes at Lower Parel, Sewri, Mazgaon, and Kalwa. It offers approximately 60 routine and 487 specialized pathology tests and around 96 basic and 130 advanced radiology investigations. Invicta Diagnostics provides a comprehensive suite of diagnostic services that includes: Routine Tests: Includes CBC, lipid profiles, liver function tests (LFT), kidney function tests (KFT), and thyroid panels Specialized Tests: Molecular diagnostics, immunoassays, infectious disease markers including dengue, COVID-19, cancer markers, and genetic panels. Sample Collection Network: Invicta uses phlebotomists and collection partners to reach patients at home or through its spoke centres. The company has a network of 5 laboratory doctors, 20 radiologists, and 127 well-trained technical staff as of May 31st, 2025. The company has 105 permanent employees as of May 31, 2025.
2021
Dr. Ketan Jayantilal Jain
Invicta Diagnostic Limited IPO
| Apply as | Price Range | Apply Upto |
|---|---|---|
| Individual (min) | ₹80-85 | ₹2,72,000 |
| Individual(max) | ₹80-85 | ₹2,72,000 |
| SHNI(min) | ₹80-85 | ₹4,08,000 |
| SHNI(max) | ₹80-85 | ₹9,52,000 |
| BHNI(min) | ₹80-85 | ₹10,88,000 |
Apply for all eligible candidates, Invicta Diagnostic Limited IPO.
NFOs are ideal for long-term investors who can wait for the fund to build performance and portfolio over time.
Yes, your mutual fund units continue to generate returns even while they are pledged for a loan.
Mutual funds carry market risk, but diversification and professional management help reduce volatility and improve long-term growth potential.
Unlike fixed-interest recurring deposits, SIP returns are market-linked and offer higher growth potential with some risk.
Yes, joint investments are allowed with a resident Indian, provided KYC and bank account norms are met.
A drop in NAV may trigger a margin call. KSquare notifies you early to take corrective actions if needed.
KSquare features only SEBI-registered, vetted NFOs and provides research insights to help investors make informed choices.
You can repay the loan in EMIs or lump sum, as per the agreed terms. KSquare offers reminders and easy tracking.